{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:58:09Z","timestamp":1788044289777,"version":"build-2784847793"},"reference-count":38,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"4","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: This study aimed to evaluate the effect of combining paricalcitol with cinacalcet on the levels of intact parathyroid hormone (iPTH) and alkaline phosphatase (ALP) in patients with secondary hyperparathyroidism undergoing maintenance hemodialysis (MHD). Methods: A retrospective analysis was conducted on the clinical records of 129 patients diagnosed with chronic kidney disease (CKD) and secondary hyperparathyroidism who received MHD between June and December 2022. The patients were categorised into three groups based on their treatment regimen: Group A (paricalcitol alone, n=43), Group B (cinacalcet alone, n=43), and Group C (combined paricalcitol and cinacalcet, n=43). Hemoglobin (Hb), serum albumin (Alb), calcium (Ca), phosphorus (P), iPTH, ALP, serum creatinine (Scr), and blood urea nitrogen (BUN) levels were measured at admission, 1 day, 3 months, and 6 months to compare the outcomes across the three groups. Results: No significant differences among the groups were observed in Hb and Alb levels at 1 day post-admission (P&gt;0.05). However, after 3 and 6 months of treatment, Hb and Alb levels increased in all groups, with Group C showing the greatest improvement (P&lt;0.05). iPTH, Ca, and P levels were similar across all groups on day 1 (P&gt;0.05), but by 3 and 6 months, all groups showed reductions, with Group C having the lowest levels (P&lt;0.05). Similarly, ALP, Scr, and BUN levels decreased in all groups over time, with Group C again demonstrating the greatest reduction (P&lt;0.05). Conclusions: The combination of paricalcitol and cinacalcet was effective in reducing iPTH, calcium, phosphorus, and ALP and improving Hb and Alb levels in patients with secondary hyperparathyroidism on maintenance hemodialysis. This treatment approach offers significant benefits in managing SHPT.<\/jats:p>","DOI":"10.5937\/jomb0-55510","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:36:09Z","timestamp":1741941369000},"page":"759-769","source":"Crossref","is-referenced-by-count":1,"title":["Clinical value of serum iPTH, ALP and serum markers levels in patients with secondary hyperparathyroidism receiving paricalcitol combined with cinacalcet"],"prefix":"10.5937","volume":"44","author":[{"given":"Song","family":"Ruifang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Fadong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zengqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xiaozhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Guti\u00e9rrez OM, et al. and Kramer H. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2017; 70(6): 737-51. https:\/\/doi.org\/10.1053\/j.ajkd.2017.07.019;","DOI":"10.1053\/j.ajkd.2017.07.019"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hu L, Napoletano A, Provenzano M, Garofalo C, Bini C, Comai G, et al. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. Int J Mol Sci 2022; 23(20). https:\/\/doi.org\/10.3390\/ijms232012223;","DOI":"10.3390\/ijms232012223"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Zhang LX, Zhang B, Liu XY, Wang ZM, Qi P, Zhang TY, et al. Advances in the treatment of secondary and tertiary hyperparathyroidism. Front Endocrinol (Lausanne). 2022; 13: 1059828. https:\/\/doi.org\/10.3389\/fendo.2022.1059828;","DOI":"10.3389\/fendo.2022.1059828"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Tokumoto M, Tokunaga S, Asada S, Endo Y, Kurita N, Fukagawa M, et al. Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism. PLoS One 2022; 17(12): e0279078. https:\/\/doi.org\/10.1371\/journal.pone.0279078;","DOI":"10.1371\/journal.pone.0279078"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Petranovi} Ov~ari~ek P, Giovanella L, Hindie E, Huellner MW, Talbot JN, et al. An essential practice summary of the new EANM guidelines for parathyroid imaging. Q J Nucl Med Mol Imaging 2022; 66(2): 93-103;","DOI":"10.23736\/S1824-4785.22.03427-6"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Fukazawa-Shinotsuka M, Saito T, Abe M, Iida S, Wang IT, T erao K, et al. Maxacalcitol Pharmacokinetic-Pharmaco - dynamic Modeling and Simulation for Secondary Hyper - parathyroidism in Patients Receiving Maintenance Hemodialysis. Drug Res (Stuttg) 2022; 72(1): 23-33. https:\/\/doi.org\/10.1055\/a-1581-7609;","DOI":"10.1055\/a-1581-7609"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Bargagli M, Arena M, Naticchia A, Gambaro G, Mazzaferro S, Fuster D, et al. The Role of Diet in Bone and Mineral Metabolism and Secondary Hyper - parathyroidism. Nutrients 2021; 13(7). https:\/\/doi.org\/10.3390\/nu13072328;","DOI":"10.3390\/nu13072328"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Li B, Chen X, Hu J, Ke G, Jiang N, Zhang F, Lian Z, Wen S, Wu Q, Xia Y, Zhang H, Kuang S, Xu L, Deng, C. and Liu, S. COMMD5 is involved in the mechanisms of hypotension after parathyroidectomy in patients receiving hemodialysis. Eur J Pharmacol 2023; 944: 175596. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175596;","DOI":"10.1016\/j.ejphar.2023.175596"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Bover J, Arana C, Ure\u00f1a P, Torres A, Mart\u00edn-Malo A, Fayos L, Coll V, et al. and Rodr\u00edguez, M. Hypo - responsiveness or resistance to the action of parathyroid hormone in chronic kidney disease. Nefrologia (Engl Ed). (2021). 41(5): 514-28. https:\/\/doi.org\/10.1016\/j.nefroe.2021.11.014;","DOI":"10.1016\/j.nefroe.2021.11.014"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Costa T, Lauar JC, Innecchi M, Coelho VA, Moys\u00e9s R and Elias RM. Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease. Int Urol Nephrol 2022; 54(9): 2255-61. https:\/\/doi.org\/10.1007\/s11255-022-03116-5;","DOI":"10.1007\/s11255-022-03116-5"},{"key":"ref11","unstructured":"Wang AY, Tang TK, Yau YY and Lo WK. Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PRO-CEED Pilot Randomized Trial. Am J Kidney Dis 2023; https:\/\/doi.org\/10.1053\/j.ajkd.2023.10.007;"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Fu J, Wang Y, Liu Y, Song Q, Cao J, Peichang W. Reference intervals for thyroid hormones for the elderly population and their influence on the diagnosis of subclinical hypothyroidism. J Med Biochem 2023; 42 (2): 258-64;","DOI":"10.5937\/jomb0-39570"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Wang N, Xie Y and Jiang G. Efficacy and safety of intravenous paricalcitol treatment in Chinese hemodialysis patients: a real-world database analysis. Ann Palliat Med. 2022; 11(1): 225-39. https:\/\/doi.org\/10.21037\/apm-21-3966;","DOI":"10.21037\/apm-21-3966"},{"key":"ref14","unstructured":"Miedziaszczyk M, Idasiak-Piechocka I, Wi\u015bniewski OW and Lacka K. A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD). Eur Rev Med Pharmacol Sci 2022; 26(1): 232-9. https:\/\/doi.org\/10.26355\/eurrev_202201_27773;"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Karaboyas A, Muenz D, Fuller DS, Desai P, Lin TC, Robinson BM, et al. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J Kidney Dis 2022; 79(3): 362-73. https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.020;","DOI":"10.1053\/j.ajkd.2021.05.020"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang Q, Chen G and Zhou T. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyper parathyroidism in Patients with Chronic Kidney Disease. Curr Pharm Des 2022; 28(40): 3289-304. https:\/\/doi.org\/10.2174\/1381612829666221027110656;","DOI":"10.2174\/1381612829666221027110656"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hasegawa T, Tokunaga S, Yamamoto T, Sakai M, Hongo H, Kawata T, et al. Evocalcet Rescues Secondary Hyper - parathyroidism-driven Cortical Porosity in CKD Male Rats. Endocrinology 2023; 164(4). https:\/\/doi.org\/10.1210\/endocr\/bqad022;","DOI":"10.1210\/endocr\/bqad022"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Akizawa T, Ikejiri K, Kondo Y, Endo Y and Fukagawa M. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial 2020; 24(3): 248-57. https:\/\/doi.org\/10.1111\/1744-9987.13434;","DOI":"10.1111\/1744-9987.13434"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Pereira L, Meng C, Amoedo M, Mendes M, Marques M, Fraz\u00e3o J, et al. Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemo - dialysis patients previously uncontrolled with cinacalcet. Nefrologia (Engl Ed) 2023; 43(2): 197-203. https:\/\/doi.org\/10.1016\/j.nefroe.2022.11.014;","DOI":"10.1016\/j.nefro.2021.09.009"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wen P, Xu L, Zhao S, Gan W, Hou D, Zhang L, et al. Risk Factors for Severe Hypocalcemia in Patients with Secondary Hyperparathyroidism after Total Para - thyroidectomy. Int J Endocrinol 2021; 2021: 6613659. https:\/\/doi.org\/10.1155\/2021\/6613659;","DOI":"10.1155\/2021\/6613659"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Takeuchi M, Takahashi T, Shodo R, Ota H, Ueki Y, Yamazaki K, et al. Comparison of Autofluorescence With Near-Infrared Fluorescence Imaging Between Primary and Secondary Hyperparathyroidism. Laryngoscope 2021; 131(6): E2097-E2104. https:\/\/doi.org\/10.1002\/lary.29310;","DOI":"10.1002\/lary.29310"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Li X, Lu Y, Zhang L, Song A, Zhang H, Pang B, et al. Primary and secondary hyperparathyroidism present different expressions of calcium-sensing receptor. BMC Surg (2023). 23(1): 31. https:\/\/doi.org\/10.1186\/s12893-023-01928-5;","DOI":"10.1186\/s12893-023-01928-5"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dream S, Kuo LE, Kuo JH, Sprague SM, Nwariaku FE, Wolf M, et al. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Mana - gement of Secondary and Tertiary Renal Hyperpara - thyroidism. Ann Surg 2022; 276(3): e141-e176. https:\/\/doi.org\/10.1097\/SLA.0000000000005522;","DOI":"10.1097\/SLA.0000000000005522"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ni Z, Liang X, Wu CC, Jin K, Kim YL, Lu KC, et al. Comparison Orchestra Study Group. Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyper - parathyroidism. Kidney Int Rep 2023; 8(11): 2294-306. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.034;","DOI":"10.1681\/ASN.20223311S193b"},{"key":"ref25","unstructured":"Faye M, Keita N, Lemrabott AT, Algouzmari I, Faye M, Mbengue M, et al. Surgical management of secondary hyperparathyroidism in dialysis patients in Senegal. Saudi J Kidney Dis Transpl 2021; 32(5): 1424-30. https:\/\/doi.org\/10.4103\/1319-2442.344763;"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, et al. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism. PLoS One 2020; 15(4): e0232428. https:\/\/doi.org\/10.1371\/journal.pone.0232428;","DOI":"10.1371\/journal.pone.0232428"},{"key":"ref27","unstructured":"Massimetti C, Imperato G and Feriozzi S. Cholecalciferol supplementation improves secondary hyperparathy-roidism control in renal transplant recipient. G Ital Nefrol 2020; 37(4);"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Gong X, Wang YA, Li C, Liao X, Li S, Yang L, et al. Effect of total parathyroidectomy in patients with secondary hyperparathyroidism: a retrospective study. Int Urol Nephrol; 2023; 55(5): 1239-45. https:\/\/doi.org\/10.1007\/s11255-022-03401-3;","DOI":"10.1007\/s11255-022-03401-3"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Xu W, Gong L, Lu J and Tang W. Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis. Exp Ther Med 2020; 20(4): 3237-43. https:\/\/doi.org\/10.3892\/etm.2020.9044;","DOI":"10.3892\/etm.2020.9044"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Reichel H, Seibert E, Tillmann FP, Barck I, Grava A, Schneider KM, et al. Economic burden of secondary hyperparathyroidism in Germany: a matched comparison. Int Urol Nephrol 2023; 55(5): 1291-300. https:\/\/doi.org\/10.1007\/s11255-022-03425-9;","DOI":"10.1007\/s11255-022-03425-9"},{"key":"ref31","unstructured":"Li P, Li G, Liu L, Huang S, Li J and Wu W. Cultivation and characterisation of primary human parathyroid cells from patients with severe secondary hyperparathyroidism. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42(2): 238-43. https:\/\/doi.org\/10.12122\/j.issn.1673-4254.2022.02.10;"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sheerah AA, Al-Ahmed RA, El-Desoky SM, Alhasan KA, Albanna AS, Shalaby MA et al. Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease. Saudi J Kidney Dis Transpl 2021; 32(6): 1628-36. https:\/\/doi.org\/10.4103\/1319-2442.352423;","DOI":"10.4103\/1319-2442.352423"},{"key":"ref33","unstructured":"Gong W, Xie Y, Lin Y, Meng Z and Wang Y. Risk factors affecting graft survival after parathyroidectomy and parathyroid autotransplantation in patients on maintenance hemodialysis. Nan Fang Yi Ke Da Xue Xue Bao. 2021; 41(6): 947-52. https:\/\/doi.org\/10.12122\/j.issn.1673-4254.2021.06.20;"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Yoshikawa K, Tsuchiya A, et al. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan. Clin Exp Nephrol 2021; 25(1): 66-79. https:\/\/doi.org\/10.1007\/s10157-020-01936-2;","DOI":"10.1007\/s10157-020-01936-2"},{"key":"ref35","unstructured":"Neagoe RM, Sala DT, Voidazan S, Arpad T, Cosma GM, Murean S, et al. A comparative analysis of three types of parathyroidectomies in renal hyperparathyroidism Single centre prospective cohort of 77 patients. Ann Ital Chir 2021; 92: 6-12;"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Chang GH, Chou FF, Tsai MS, Tsai YT, Yang MY, Huang EI, et al. Real-world evidence and optimisation of vocal dysfunction in end-stage renal disease patients with secondary hyperparathyroidism. Sci Rep 2021; 11(1): 653. https:\/\/doi.org\/10.1038\/s41598-020-79810-0;","DOI":"10.1038\/s41598-020-79810-0"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Li X, Ding W and Zhang H. Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review. Front Endocrinol (Lausanne) 2023; 14: 1146955. https:\/\/doi.org\/10.3389\/fendo.2023.1146955;","DOI":"10.3389\/fendo.2023.1146955"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Ketteler M, Martin KJ, Cozzolino M, Goldsmith D, Sharma A, Khan S, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant 2012; 27(5): 1942-9;","DOI":"10.1093\/ndt\/gfr531"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Klini\u010dki zna\u010daj nivoa serumskog iPTH, ALP i serumskih markera kod pacijenata sa sekundarnim hiperparatireoidizmom koji primaju parikalcitol u kombinaciji sa cinakalcetom"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582504759R.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T14:50:40Z","timestamp":1751640640000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582504759R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-55510","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}